TN2009000427A1 - Use of hdac inhibitors for the treatment of gastrointestinal cancers - Google Patents

Use of hdac inhibitors for the treatment of gastrointestinal cancers

Info

Publication number
TN2009000427A1
TN2009000427A1 TNP2009000427A TN2009000427A TN2009000427A1 TN 2009000427 A1 TN2009000427 A1 TN 2009000427A1 TN P2009000427 A TNP2009000427 A TN P2009000427A TN 2009000427 A TN2009000427 A TN 2009000427A TN 2009000427 A1 TN2009000427 A1 TN 2009000427A1
Authority
TN
Tunisia
Prior art keywords
treatment
gastrointestinal cancers
hdac inhibitors
hdac inhibitor
gastrointestinal
Prior art date
Application number
TNP2009000427A
Other languages
French (fr)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39683987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000427A1 publication Critical patent/TN2009000427A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)

Abstract

The present invention relates to the use of an HDAC inhibitor for the preparation of a medicament for the treatment of gastrointestinal cancers; a method of treating a warm-blooded animal, especially a human, having gastrointestinal cancer, comprising administering to said animal a therapeutically effective amount of an HDAC inhibitor, especially a compound of formula (I) as defined herein; and to a pharmaceutical composition and a commercial package.
TNP2009000427A 2007-05-04 2009-10-16 Use of hdac inhibitors for the treatment of gastrointestinal cancers TN2009000427A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91599607P 2007-05-04 2007-05-04
PCT/US2008/062341 WO2008137630A1 (en) 2007-05-04 2008-05-02 Use of hdac inhibitors for the treatment of gastrointestinal cancers

Publications (1)

Publication Number Publication Date
TN2009000427A1 true TN2009000427A1 (en) 2011-03-31

Family

ID=39683987

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000427A TN2009000427A1 (en) 2007-05-04 2009-10-16 Use of hdac inhibitors for the treatment of gastrointestinal cancers

Country Status (16)

Country Link
EP (1) EP2142190A1 (en)
JP (1) JP2010526149A (en)
KR (1) KR20100016171A (en)
CN (1) CN101674825A (en)
AU (1) AU2008247603A1 (en)
BR (1) BRPI0811112A2 (en)
CA (1) CA2683554A1 (en)
CL (1) CL2008001269A1 (en)
IL (1) IL201318A0 (en)
MA (1) MA31356B1 (en)
MX (1) MX2009011692A (en)
RU (1) RU2009144842A (en)
TN (1) TN2009000427A1 (en)
TW (1) TW200908964A (en)
WO (1) WO2008137630A1 (en)
ZA (1) ZA200906739B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (en) * 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
EP1682538A4 (en) * 2003-10-27 2009-05-27 S Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
AR046920A1 (en) * 2003-10-27 2006-01-04 S Bio Pte Ltd HYDROXAMATES CONNECTED TO ACILUREA AND CONNECTED TO SULFONILUREA
WO2006075165A1 (en) * 2005-01-13 2006-07-20 Btg International Limited Combination of oncolytic viruses with angiogenesis inhibitors

Also Published As

Publication number Publication date
WO2008137630A1 (en) 2008-11-13
JP2010526149A (en) 2010-07-29
TW200908964A (en) 2009-03-01
CN101674825A (en) 2010-03-17
CL2008001269A1 (en) 2008-12-19
MX2009011692A (en) 2009-11-10
ZA200906739B (en) 2010-06-30
AU2008247603A1 (en) 2008-11-13
KR20100016171A (en) 2010-02-12
MA31356B1 (en) 2010-05-03
RU2009144842A (en) 2011-06-10
CA2683554A1 (en) 2008-11-13
IL201318A0 (en) 2010-05-31
EP2142190A1 (en) 2010-01-13
BRPI0811112A2 (en) 2014-12-23

Similar Documents

Publication Publication Date Title
EA201300860A1 (en) CRYSTALLINE TRIPEPTIDE EPOXYKETON-PROTEASE INHIBITORS
TW200833663A (en) Therapeutic agents
EA201290184A1 (en) BENZODIAZEPINUM INHIBITOR BROMODOMENE
HK1131608A1 (en) Pyridinone compounds
MX2007009649A (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer.
MY183014A (en) Compounds for enzyme inhibition
EA201290183A1 (en) BENZODIAZEPINUM INHIBITOR BROMODOMENE
TN2011000291A1 (en) Purine compounds
GEP20125599B (en) Proteasome inhibitors
EA201290516A1 (en) HETEROAROMATIC DERIVATIVES OF PHENYLIMIDAZOLE AS A PDE10A ENZYME INHIBITOR
IN2014MN00139A (en)
ZA200806778B (en) N-Hydroxyacrylamide compounds
TW200806299A (en) Treatment of pain
EA201001196A1 (en) 4-PYRIDINONE COMPOUNDS AND THEIR APPLICATION FOR CANCER TREATMENT
MX2013012588A (en) Kinase inhibitors.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2009026446A3 (en) Hdac inhibitors
GEP201606513B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
EA201170344A1 (en) AZAINDOL IAP INHIBITORS
WO2009015368A3 (en) Multikinase inhibitors for use in the treatment of cancer
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
TW200719903A (en) Compositions for the treatment of neoplasms